• Baseline demographic and clinical characteristics will be compared between treatment groups and characteristics showing clinically or statistically significant differences will be considered as covariates.
  
• All tests of hypotheses will be twotailed.
  
• Any participants with undetectable prednisone or prednisolone levels at exit will be judged to be nonadherent with this medication and excluded from the analysis.
  
• Intent to treat sample can be defined either as everyone who receives study drug or everyone who returns for at least one postbaseline visit.
  
• If they do not return for at least one postbaseline visit we will not have data on study drug (or on prednisone) for the analyses.
  
• Since we have two postbaseline visits, if we only tested those who come to both then that would be a completion analysis; therefore, we will use any participants who come to at least one postbaseline visit on medication (ITT sample) in the analysis.
  
• Given a small sample size we may not have statistical power to detect significant between group differences if the effect size is not large.
  
• However, this pilot study will provide the necessary information to power a larger, more definitive study funded by NIH.
  

Inclusion Criteria:

• Age 18-65
• Scheduled to receive at least 20 mg/day of prednisone for at least 7 days
• Baseline RAVLT total score of ≥40

Exclusion Criteria:

• History of allergic reaction or other contraindication to acetaminophen therapy
• Acetaminophen use within 24 hours of study entry
• History of liver disease or alcohol use of greater than 3 drinks/day
• Severe or unstable medical condition (e.g., recent myocardial infarction,renal failure, diabetes with poor glycemic control)
• Pregnant or lactating female
• Patient has mental retardation, dementia, or other severe cognitive disorder